Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio- 5-fluorocytidine

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1127-1131

  Richard, Nathalie ^a,b   Salomon, Horacio ^a   Rando, Robert ^c   Mansour, Tarek ^c   Bowlin, Terry L ^c   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Shire Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 3' OXA 4' THIO 5 FLUOROCYTIDINE; CYTIDINE DERIVATIVE; DNA POLYMERASE; DOUBLE STRANDED DNA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; ENANTIOMER; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS;

ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, MICROBIAL; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIONUCLEOSIDES;

EID: 0034090290     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1127-1131.2000     Document Type: Article

References (42)

1. Arion, D., and M. Parniak. 1999. HIV resistance to zidovudine: the role of pyropnosphorolysis. Drug Resist. Updates 2:91-95.
2. Arion, D., N. Kaushik, S. McCormick, G. Borkow, and M. A. Parniak. 1998. HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased DNA polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37:15908-15917.
3. Arts, E. J., J.-P. Marois, Z. Gu, S. F. J. Le Grice, and M. A. Wainberg. 1996. Effects of 3′-deoxynucleotide 5′-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type-1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70: 712-7211.
4. Back, N. K. T., M. Nijhuis, W. Keulen, C. A. B. Boucher, B. B. Oude Essink, A. B. P. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
5. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
6. Boucher, C. A. B., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. A. Lang, J. Goodsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
7. Boulerice, F., S. Bour, R. Geleziunas, A. Lvovich, and M. A. Wainberg. 1990. High frequency of isolation of defective human immunodeficiency virus type-1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J. Virol. 64:1745-1755.
8. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
9. Canard, B., S. R. Sarfati, and C. C. Richardson. 1998. Enhanced binding of azidothymidine-resistant human immunodeficiency virus type 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′ monophosphate-terminated primer. J. Biol. Chem. 273:14596-14604.
10. Fisher, A. G., E. Collalti, L. Ratner, R. C. Gallo, and F. Wong-Staal. 1985. A molecular clone of HTLV-III with biological activity. Nature (London) 316:262-265.
11. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
12. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
13. Gao, W.-Y., A. Cara, R. C. Gallo, and F. Lori. 1993. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 90: 8925-8928.
14. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
15. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
16. Harrigan, P. R., I. Kinghorn, S. Bloor, S. D. Kemp, I. Najera, A. Kohli, and B. A. Larder. 1996. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J. Virol. 70:5930-5934.
17. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vézinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kurtzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 279:1984-1991.
18. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-thymidine. J. Virol. 70:8010-8018.
19. Hsu, M., P. Inouye, L. Rezende, N. Richard, Z. Li, V. R. Prasad, and M. A. Wainberg. 1997. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res. 25:4532-4536.
20. Huang, H., R. Chopra, G. L. Verdine, and S. C. Harrison. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
21. Huber, H. E., J. M. McCoy, J. S. Seehra, and C. C. Richardson. 1989. Human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 264: 4669-4678.
22. Kati, W. M., K. A. Johnson, L. F. Jerva, and K. S. Anderson. 1992. Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem. 267:25988-25997.
23. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, Jr., R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir. Res. 28:133-145.
24. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
25. Keulen, W., N. K. T. Back, A. van Wijk, C. A. B. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3340-3350.
26. Larder, B. A., S. Bloor, S. D. Kemp, K. Hertogs, R. L. Desmet, V. Miller, M. Stunner, S. Staszewski, J. Ren, K. Stammers, D. I. Stuart, and R. Pauwels. 1999. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob. Agents Chemother. 43:1961-1967.
27. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
28. Mansour, T. S., H. Jin, W. Wang, E. Hooker, C. Ashman, N. Cammack, H. Salomon, A. R. Belmonte, and M. A. Wainberg. 1995. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J. Med. Chem. 38:1-4.
29. Mansour, T. S., H. Jin, W. Wang, D. M. Dixit, C. A. Evans, H. L. A. Tse, B. Belleau, J. W. Gillard, E. Hooker, C. Ashman, N. Cammack, H. Salomon, A. R. Belmonte, and M. A. Wainberg. 1995. Structure-activity relationships among a new class of antiviral heterosubstituted 2′,3′-dideoxynucleoside analogues. Nucleosides Nucleotides 14:627-635.
30. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
31. Richard, N., Y. Quan, H. Salomon, M. Hsu, J. Bedard, R. Rando, T. Mansour, T. L. Bowlin, and M. A. Wainberg. 1999. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC). Antivir. Ther. 4:171-177.
32. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
33. Salomon, H., Z. Gu, Q. Gao, K. Nagai, J. Hiscott, and M. A. Wainberg. 1995. Host cell dependence of human immunodeficiency virus type-1 drug resistance profiles and tissue culture selection pattern. Antivir. Chem. Chemother. 6:222-229.
34. Sarafianos, S. G., K. Das, A. D. Clark, J. Ding, P. L. Boyer, S. H. Hughes, and E. Arnold. 1999. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl. Acad. Sci. USA 96:10027-10032.
35. Schinazi, R. F., R. M. Lloyd, Jr., M. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
36. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
37. St-Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
38. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. A. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:369-384.
39. Tisdale, M., T. Alnadaf, and D. Consens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.
40. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
41. Wainberg, M. A., and G. Friedland. 1998. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983.
42. Yu, H., and M. F. Goodman. 1992. Comparison of HIV-1 and avian myeloblastosis virus reverse transcriptase fidelity on RNA and DNA templates. J. Biol. Chem. 267:10888-10896.